Showing 3021-3040 of 8668 for: Cochrane Systematic Reviews Back
- Glutamine for induction of remission in Crohn's disease
Cochrane Systematic Reviews, 8-Feb-2016
Crohn's disease is a chronic relapsing condition of the alimentary tract with a high morbidity secondary to bowel inflammation. Glutamine plays a key role in maintaining the integrity of the intestinal mucosa and has been shown to reduce inflammation and
- Glutamine supplementation for critically ill adults
Cochrane Systematic Reviews, 9-Sep-2014
Glutamine is a non-essential amino acid which is abundant in the healthy human body. There are studies reporting that plasma glutamine levels are reduced in patients with critical illness or following major surgery, suggesting that glutamine may be a cond
- Glutamine supplementation for young infants with severe gastrointestinal disease
Cochrane Systematic Reviews, 15-Dec-2014
Endogenous glutamine biosynthesis may be insufficient to meet the needs of people with severe gastrointestinal disease. Results from studies using experimental animal models of gastrointestinal disease have suggested that glutamine supplementation improve
- Glutamine supplementation to prevent morbidity and mortality in preterm infants
Cochrane Systematic Reviews, 18-Apr-2016
Glutamine is a conditionally essential amino acid. Endogenous biosynthesis may be insufficient for tissue needs in states of metabolic stress. Evidence exists that glutamine supplementation improves clinical outcomes in critically ill adults. It has been
- Gluten- and casein-free diets for autistic spectrum disorder
Cochrane Systematic Reviews, 2-Apr-2019
It has been suggested that peptides from gluten and casein may have a role in the origins of autism and that the physiology and psychology of autism might be explained by excessive opioid activity linked to these peptides. Research has reported abnormal l
- Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants
Cochrane Systematic Reviews, 30-Sep-2015
Feeding intolerance is a common clinical problem among preterm infants. It may be an early sign of necrotising enterocolitis, sepsis or other serious gastrointestinal conditions, or it may result from gut immaturity with delayed passage of meconium. Glyce
- Glycerol for acute stroke
Cochrane Systematic Reviews, 19-Apr-2004
Brain oedema is a major cause of early death after stroke. A 10% solution of glycerol is a hyperosmolar agent that is claimed to reduce brain oedema.
- Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke
Cochrane Systematic Reviews, 18-Feb-2014
Glycoprotein (GP) IIb-IIIa inhibitors are antiplatelet agents that act by antagonising GP IIb-IIIa receptors on the platelet surface and block the final common pathway to platelet aggregation by preventing the binding of fibrinogen molecules that form bri
- GM‐CSF (granulocyte macrophage colony‐stimulating factor) supplementation in culture media for women undergoing assisted reproduction
Cochrane Systematic Reviews, 16-Jul-2020
GM-CSF (granulocyte macrophage colony-stimulating factor) is a growth factor that is used to supplement culture media in an effort to improve clinical outcomes for those undergoing assisted reproduction. It is worth noting that the use of GM-CSF-supplemen
- Goal setting and strategies to enhance goal pursuit for adults with acquired disability participating in rehabilitation
Cochrane Systematic Reviews, 15-Jul-2015
Goal setting is considered a key component of rehabilitation for adults with acquired disability, yet there is little consensus regarding the best strategies for undertaking goal setting and in which clinical contexts. It has also been unclear what effect
- Gold as an oral corticosteroid sparing agent in stable asthma
Cochrane Systematic Reviews, 23-Oct-2000
Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that
- Golimumab for rheumatoid arthritis
Cochrane Systematic Reviews, 20-Jan-2010
Golimumab is a humanized inhibitor of Tumor necrosis factor-alpha, recently approved by the Food and Drug Administration (FDA) for the treatment of Rheumatoid arthritis (RA).
- Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome
Cochrane Systematic Reviews, 24-Aug-2015
Approximately 15% of women with PCOS remain anovulatory despite treatment with oral anti-oestrogen medications such as clomiphene citrate. In addition, about half of women with PCOS ovulating on anti-oestrogen treatment fail to conceive. Gonadotrophin sti
- Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles
Cochrane Systematic Reviews, 17-Jul-2008
Gonadotropin releasing hormone agonists (GnRHa) are used in assisted reproduction cycles to reversibly block pituitary function and prevent a luteinizing hormone surge. In the short and ultrashort protocols of GnRHa administration, injection of gonadotrop
- Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Cochrane Systematic Reviews, 9-Nov-2015
Gonadotrophin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising
- Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome
Cochrane Systematic Reviews, 17-Jul-2008
Elevation of endogenous LH levels may result in premature luteinization. This may also be associated with the increased rate of spontaneous abortion. Gonadotropin releasing hormone analogue (GnRHa) used prior to human menopausal gonadotropin (hMG/FSH) adm
- Gonadotrophin‐releasing hormone analogues for endometriosis: bone mineral density
Cochrane Systematic Reviews, 20-Oct-2003
Gonadotrophin-releasing hormone analogues (GnRHas) are generally well tolerated, and are effective in relieving the symptoms of endometriosis (Prentice 2003). Unfortunately the low oestrogen state that they induce is associated with adverse effects includ
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Cochrane Systematic Reviews, 16-Mar-2010
Endometriosis is a common gynaecological condition that frequently presents with the symptom of pain. The precise pathogenesis (mode of development) of endometriosis is unclear but it is evident that endometriosis arises by the dissemination of endometriu
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Cochrane Systematic Reviews, 1-Nov-2010
Endometriosis is a common gynaecological condition, characterised by the presence of endometrial tissue in sites other than the uterine cavity (excluding adenomyosis) that frequently presents with pain. The gonadotrophin-releasing hormone analogues (GnRHa
- Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology
Cochrane Systematic Reviews, 29-Apr-2016
Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-effects, flare-up, or long down-regulation period associated with
